Fcpm III Services B.V.
Fcpm III Services B.V. reported 11 US-listed holdings worth $750.4 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Newamsterdam Pharma Company (38.3%), Maplight Therapeutics Inc. (15.4%) and Dyne Therapeutics Inc. (11.4%). Against the quarter before, it opened 1 position, added to 0, trimmed 2 and sold out of 0.
The 11 largest of its 11 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +20.1% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 1
- Aura Biosciences Inc. AURA$28.8 million
Trimmed 2
- Newamsterdam Pharma Company NAMS-708,547 shares · -8%
- Dyne Therapeutics Inc. DYN-796,130 shares · -17%
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Newamsterdam Pharma Company NAMS | 8.5M | $287.7 million | 38.34% | -708.5K |
| Maplight Therapeutics Inc. MPLT | 3.2M | $115.6 million | 15.41% | no change |
| Dyne Therapeutics Inc. DYN | 3.8M | $85.5 million | 11.39% | -796.1K |
| Vor Biopharma Inc. VOR | 4.1M | $75.8 million | 10.10% | no change |
| Galecto Inc. DMRA | 2.4M | $63.5 million | 8.46% | no change |
| Replimune Group, Inc. REPL | 2.8M | $31.1 million | 4.14% | no change |
| Crescent Biopharma Inc. CBIO | 1.7M | $30.2 million | 4.02% | no change |
| Aura Biosciences Inc. AURA | 4.1M | $28.8 million | 3.84% | new |
| Engene Holdings Inc. ENGN | 9.6M | $16.7 million | 2.22% | no change |
| Bicycle Therapeutics PLC BCYC | 3.5M | $14.7 million | 1.96% | no change |
| Engene Holdings Inc. ENGNW | 2.9M | $834,376 | 0.11% | no change |